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Abstract
Background: Vitamin D receptor (VDR) is a well known transcriptional regulator, active as heterodimer in association with
coactivators and corepressors. In addition it has been described the extranuclear distribution of the receptor and in
particular the recently reported mitochondrial localization in platelets and megakaryocytes is intriguing because it appears
to be a common feature of steroid receptors. Whereas for other members of the steroid receptor family the mitochondrial
function has been explored, up to now nothing is known about a mitochondrial form of VDR in human proliferating cells.
Methodology/Principal Findings: In this study we characterized for the first time the mitochondrial localization of VDR in
the human keratinocyte cell line HaCaT. In proliferating HaCaT cells VDR was abundantly expressed in mitochondria in
association with its binding partner RXRa and the import was ligand-independent. By immunoprecipitation studies we
demonstrated the interaction of VDR with proteins of the permeability transition pore (PTP), VDAC and StAR. We then
adopted different pharmacological and silencing approaches with the aim of hampering PTP function, either affecting PTP
opening or abating the expression of the complex member StAR. By all means the impairment of pore function led to a
reduction of mitochondrial levels of VDR.
Conclusions: The results reported here demonstrate a ligand-independent mitochondrial import of VDR through the
permeability transition pore, and open interesting new perspectives on PTP function as transporter and on VDR role in
mitochondria.
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Introduction
Vitamin D (the active form 1,25-dihydroxyvitamin D3,
1,25D3) exerts its antiproliferative and differentiating properties
through its receptor (VDR). Like other members of the steroid
hormone receptors family, VDR is well known as transcriptional
factor and carries on its function upon nuclear translocation,
heterodimerization with RXRa and association with coactiva-
tors or corepressors to VDRE regions of DNA. VDR activity is
controlled by p53, which both induces receptor expression and
synergizes with it at VDRE sites [1]. With this mechanism, for
example, p53 and VDR trigger cell cycle arrest through p21
(waf1/cip1) action [2]. Besides their classical nuclear function
for many steroid receptors a non genomic signalling pathway
has been described, either plasma membrane bound or at
mitochondrial level. Steroid receptors such as RXRa, thyroid
receptor (TR), glucocorticoid receptor (GR), estrogen receptor
(ER) show an additional mitochondrial localization which
suggests a role either in mitochondrial biogenesis or metabolism
[3–5]. Many nuclear transcription factors may participate in
regulating mitochondrial function through transcriptional regu-
lation of mitochondrial DNA [6].
Also p53 can translocate to mitochondria, where it is involved in
apoptosis. The transcription independent pathway of p53 medi-
ated apoptosis has been described as a destabilization of the outer
mitochondrial membrane by complexing with the anti-apoptotic
proteins Bcl-xL and Bcl2 and by activation of the cytoplasmic
proapoptotic protein Bax [7].
Apart from our previous work on human platelets and
megakaryocytes, where we described a VDR located in mito-
chondria [8], there are very few evidences of a mitochondrial
localization for VDR, presented as mere observations [9–11]. The
aim of this work was therefore to characterize VDR subcellular
distribution in proliferating human cells. We carried out our study
on a cellular model highly expressing VDR, the HaCaT cell line, a
spontaneously transformed human epithelial cell line from adult
skin which is immortal but maintains full epidermal differentiation
capacity [12]. Human keratinocytes not only respond to vitamin D
with changes in proliferation and differentiation but also
synthesize vitamin D and its metabolites [13]. HaCaT cells
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express nuclear VDR and have been used as a model for the
investigation of the vitamin D pathway and its modulation [14].
In this study, we discovered that VDR, besides its nuclear
expression, can localize also in the mitochondria of human
proliferating cells and that VDR mitochondrial import requires
permeability transition pore (PTP) stability and functioning. These
observations provide new insight into VDR localization and put
forward a novel mechanism whereby a receptor can be imported
into the mitochondria.
Materials and Methods
Cell Culture and Treatments
Immortalized human epidermal keratinocytes (HaCaT) were
purchased from American Type Culture Collection (ATCC),
USA, and were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum and 1%
antibiotics [penicillin-streptomycin (Sigma-Aldrich)] at 37uC in
humidified 5% CO2 atmosphere. When treated, cells were kept in
the same medium supplemented with 1% fetal bovine serum. Cells
were incubated for reported time with 1 or 100 nM 1,25(OH)2
vitamin D3 (Sigma), 10 mM squalestatin (zaragozig acid, Sigma),
5 mg/ml cycloheximide, 5 mM cyclosporine A, 100 nM dexa-
methasone, with periodical replacement of medium. Latter drugs
were from Calbiochem, La Jolla, CA. Other reagents were from
Sigma.
Primary Antibodies
As previously described [8], the following antibodies against
VDR were used: rabbit polyclonal anti-VDR (C-terminus
fragment) clone C-20 (sc-1008, Santa Cruz Biotechnology, CA);
rat monoclonal anti-VDR biotin labeled (aa 89–105 epitope) clone
9A7c.E10.E4 (RT-200-B, LabVision NeoMarkers, CA). The
antibody against RXRa was commercially available from Santa
Cruz (rabbit antibody D-20 against N-terminus of human RXRa),
whereas the biotinylated form was made in our laboratory
conjugating biotin to mouse antibody against aa 198–462 of
human RXRa (clone F-1, Santa Cruz). Briefly, after removing
gelatin from IgG, the antibody was labeled with biotin by EZ-Link
Micro Sulfo-NHS-Biotinylation kit (Pierce) following the indica-
tions of the manufacturer. Sulfo-NHS-LC-Biotin was used in
labeling reaction, followed by excess biotin removal and storage of
biotinylated antibody in 2 mM BSA, 0,02% Na Azide.
Monoclonal antibody anti-VDAC (anti-porin 31HL) was
purchased from Calbiochem. Mouse monoclonal antibodies anti-
actin (sc-8432) and anti-StAR (sc-166821) and rabbit antibody
anti-PARP (sc-7150) were from Santa Cruz, CA, USA.
Extracts Preparation
Subcellular fractionation was carried out following the proce-
dure described by Capiati et al. [15], with some modifications.
Cells were scrapped from the dishes and homogenized in a glass
hand homogenizer in 10 mM Tris-HCl, pH 7.4, 0.33 M sucrose,
1 mM EDTA, 1 mM dithiothreitol, 1 mM phenylmethylsulpho-
nyl fluoride (PMSF), 1 mM protease inhibitors Cocktail set III
(Calbiochem), 1 mM Na3VO3, 1 mM NaF. An aliquot was kept
for protein analysis (total extract) before the lysates were subjected
to differential centrifugation, first at 200 g for 10 min to eliminate
cell debris, followed by 1,000 g for 10 min to isolate the nuclear
fraction, and 14,300 g for 20 min to obtain a soluble fraction as
supernatant and the mitochondrial fraction as a pellet. The latter
was resuspended in boiling sample buffer (SB 1X: 100 mM Tris–
HCl, pH 6.8, 0.01% bromophenol Blue, 2% SDS, 15% glycerol,
10 mM DTT). Proteins were extracted from nuclei by incubation
in boiling sample buffer followed by sonication. Nuclear debris was
finally centrifuged for 15 min at 16,0006g at 4uC and superna-
tants, corresponding to nuclear extracts, were kept for protein
analysis. All fractions were quantified for protein content by DC
protein assay Biorad.
Immunoprecipitation and Western Blotting
For immunoprecipitation studies, the mitochondrial fraction
obtained as described above was resuspended in RIPA buffer
(10 mM Tris pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, 1 mM protease inhibitors, 1 mM
PMSF). 300 mg of proteins were incubated with rotation overnight
at 4uC with 1 mg of antibody, followed by an additional incubation
for 2 h with protein G agarose beads. Proteins were collected by
centrifugation after boiling in SB 1x. All subcellular fractions and
immune complexes were separated by 10% SDS-PAGE and then
transferred overnight to PVDF membranes (Immobilon-P, Milli-
pore, Bedford, MA). Western blotting analysis was performed as
described previously [16]. Proteins were immunostained with the
indicated primary antibodies for 1 h at room temperature.
Detection of protein of interest was performed using peroxidase-
conjugated secondary antibodies (Pierce, Rockford, IL) followed
by ECL detection (ECL detection kit, Perkin Elmer Life Science,
Boston, MA, USA). Because of the similar molecular weight of
VDR, RXRa and IgG heavy chain, the identification of VDR and
RXRa from immunoprecipitates was carried out with the
biotinylated 9A7c primary antibody and biotinylated RXRa
antibody respectively, followed by a streptavidin-HRP incubation
and ECL detection.
Lentivirus Production and Cellular Transduction
PLKO.1 lentiviral vectors expressing the shRNAs against
human VDR (TRCN0000019506), human StAR
(TRCN0000040223) and the non-target control shRNA
(SHC002) were purchased from SIGMA Aldrich. Lentiviral
transduction particles were produced in HEK293T cells by co-
transfection of either the control or the human VDR or StAR
shRNA plasmid together with packaging vectors pMDLg/pRRE,
pRSVRev, and pMD2.VSVG. Lipofectamine 2000 (LifeTechnol-
ogies) was used as transfection reagent. Supernatants were
harvested 30 hours after transfection, filtered through 0.22-Am
pore size filters (Corning Science Products) and used directly for
over/night trasduction of HaCaT keratinocytes. Puromycin
selection started 24 hours after HaCaT infection. Five days after
infection cells were harvested, mitochondria and nuclei were
separated as described above and proteins from different fractions
were analysed by western blotting for StAR and VDR expression
levels.
Bands Quantification and Statistical Analysis
Bands from protein electrophoresis were quantified by scanning
digital densitometry using an ImageJ software analysis (ImageJ
version 1.29, Sun Microsystems Inc., Palo Alto, CA). Statistical
analysis of data was performed using ANOVA test with Tukey’s
post-hoc correction. p values ,0.05 were considered significant
and indicated when treatments were compared to control. All data
were expressed as mean 6 S.D.
Results
HaCaT Cells Express a Mitochondrial form of VDR and
RXRa
First of all we decided to characterize the subcellular
distribution of the receptor in HaCaT cells untreated or treated
VDR Mitochondrial Translocation
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with 1 nM or 100 nM 1,25-dihydroxyvitamin D3 for 24 hours.
Total extracts were fractionated by differential centrifugation in
soluble, mitochondrial and nuclear preparations and each fraction
was analysed by western blotting. The rabbit polyclonal antibody
C-20 recognized with specificity VDR protein at the reported
molecular weight of about 50 kDa, as demonstrated in our
previous work [8]. As shown in figure 1A, VDR was evident in
total lysates and the fractionation procedure led to the intensifi-
cation of receptor expression both in nuclear extracts and in the
mitochondrial fraction. Mitochondrial and nuclear enrichment
was evaluated by analysis of VDAC in mitochondrial fraction and
PARP in nuclear samples. VDR expression was not affected by
vitamin D treatment at two different concentrations. The analysis
of the same samples revealed also a strong mitochondrial
expression of RXRa (fig. 1B). Mitochondrial and nuclear VDR
expression was confirmed by knockdown experiments. Upon
silencing of the receptor by lentiviral shRNA delivery the protein
disappeared from mitochondrial and nuclear extracts, as shown in
figure 1C.
VDR Associates to the Permeability Transition Pore (PTP)
Components
In order to investigate the mechanism of mitochondrial import
of VDR, we hypothesized that VDR translocation could be
mediated by the classical import machinery known as TOM/TIM
translocase. However, upon analysis by protein subcellular
localization prediction methods (Mitoprot II, TargetP 1.1,
Predotar, iPSORT, WoLFPSORT) we could not find any import
sequence at the N-terminal of the receptor. Therefore we took into
consideration the possibility that VDR might cross the mitochon-
drial membranes through the permeability transition pore, a
complex up to now little investigated as import channel. To verify
this possibility we performed some experiments aimed at
demonstrating the interaction between VDR and the proteins of
PTP. We chose to investigate a possible association of VDR with
VDAC and StAR, two components of the outer membrane layer
of PTP. By immunoprecipitation studies we found that in the
mitochondrial fractions VDR interacted with RXRa, as reason-
ably expected since RXRa is a known binding partner of VDR
(fig. 2A). Most interesting, we obtained the evidence that VDR
and RXRa associated with VDAC, as shown in figure 2A, and
StAR, as demonstrated by figure 2B.
Blocking the Opening of PTP Hampers VDR
Mitochondrial Import
We set up experimental conditions able to demonstrate that
closing PTP interfered with VDR mitochondrial translocation. We
treated HaCaT cells for 18 hours with an inhibitor of protein
synthesis (cycloheximide, CHX) and an inhibitor of PTP function
(cyclosporin A, CsA) [17]. The combined treatment allowed us to
distinguish two mitochondrial protein pools, because CsA
sequesters into mitochondria proteins dependent solely on PTP
for their translocation. In presence of CsA, CHX-insensitive pool
is made of proteins confined into mitochondria and therefore
insensitive to synthesis inhibition, whereas CHX-sensitive proteins
are synthesized and imported by TOM/TIM translocase [18].
After the cotreatment CHX was washed out and cells were
incubated for additional 24 hours with or without CsA in presence
or absence of vitamin D. We analysed protein content of
mitochondrial fractions by western blotting and evaluated the
expression of VDR, RXRa and p53, which are proteins able to
translocate to mitochondrial compartment by different mecha-
nisms. All values were normalized for VDAC expression, which
was constant in all conditions, and results are shown in figure 3.
Representative images of blots are displayed in figure S1. As
demonstrated by graph in fig. 3A, 42 hours of treatment with CsA
resulted in a marked reduction of VDR, and allowed an evaluation
of a t1/2 of 48 hours for mitochondrial VDR. Cotreatment with
CHX and CsA for 18 hours decreased only slightly and not
significantly mitochondrial import of VDR, and only if the
Figure 1. VDR expression and subcellular distribution in HaCaT cells. Cell were incubated for 24 hours alone (control, C) or with 1 or 100 nM
1,25D3 (D1 or D100) and harvested. (A) After subcellular fractionation procedures 50 mg of proteins from total extracts (TOT) and soluble fraction
(SOL), and 10 mg of proteins from mitochondria (MIT) and nuclear extracts (N) were separated by SDS-PAGE and analysed by western blotting for VDR
expression. Equal loading and quality of samples was confirmed by reprobing the membranes with antibodies anti actin, VDAC (mitochondrial
marker) and PARP (nuclear marker). (B) Same amount of total extracts and mitochondrial fractions were analysed by western blotting for RXRa
expression. (C) 10 mg of proteins from mitochondria (MIT) and nuclear extracts (N) of untreated cells (ctrl) or cells infected with shRNA control and
shRNA anti-VDR were analysed by western blotting for VDR expression and afterwards for loading uniformity.
doi:10.1371/journal.pone.0054716.g001
VDR Mitochondrial Translocation
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cotreatment was followed by incubation with CsA for further 24
hours VDR import was hampered, whereas if vit. D or medium
alone was added VDR import was similar to control. These
experiments demonstrated that VDR import is CHX insensitive
and CsA dependent, and therefore mediated by PTP. In the same
conditions quantification of mitochondrial RXRa gave different
results, as shown by graph in fig. 3B. Mitochondrial import of this
receptor was CHX-dependent; in fact it was only slightly altered in
presence of CsA alone whereas it strongly decreased upon
cotreatment of CsA with CHX for 18 hours. Eliminating CHX
from incubation medium in the following 24 hours restored
mitochondrial content of RXRa but in presence of CsA to a
significantly lesser extent. We therefore reached the conclusion
that mitochondrial import of RXRa CHX-dependent and mildly
sensitive to CsA, was mainly mediated by a translocase. Finally,
analysis of mitochondrial p53 presented in graph 3C revealed a
strong decrease in presence of CHX, which is in agreement with
the short half-life of the protein, whereas CsA had the opposite
effect on the protein, increasing mitochondrial p53.
Squalestatin Decreases StAR Expression and VDR
Mitochondrial Import
The second pharmacological approach aimed at affecting PTP
functioning was down-regulating the expression of StAR, one key
Figure 2. VDR association with RXRa and PTP proteins. (A)
Mitochondrial extracts from untreated HaCaT cells were immunopre-
cipitated with anti-VDR and anti-RXRa rabbit antibody and detection by
western blotting was performed with anti-VDR or anti-RXRa biotiny-
lated antibodies and with anti-VDAC rabbit antibody. (B) The interaction
between VDR, RXRa and StAR was investigated in mitochondrial
fraction by immunoprecipitation with anti-StAR rabbit antibody
followed by western blotting and detection with anti-VDR and anti-
RXRa biotinylated antibodies. In every assay a 10% input was used as a
positive control and immunoprecipitation with normal IgG as negative
control.
doi:10.1371/journal.pone.0054716.g002
Figure 3. Analysis of mitochondrial translocation of VDR in
presence of cyclosporin A. HaCaT cells were treated with
cyclosporin A (CsA), cycloheximide (CHX) or 100 nM 1,25D3 (Vit.D) as
indicated and 30 mg of mitochondrial proteins were analysed by
western blotting for VDR, RXRa and p53 expression. Bands were
quantified, normalized for loading as a ratio to VDAC expression and
data plotted on graph as percentage of control. Data represent the
mean 6 S.D of three independent experiments. *p,0.05 and
**p,0.001 compared to control. # p,0.05 vs CHX CsA 18 h+vit.D 24 h.
doi:10.1371/journal.pone.0054716.g003
VDR Mitochondrial Translocation
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protein of the complex. StAR was first characterized as
mitochondrial transporter of cholesterol in cells active in steroids
biosynthesis, and in second instance it was recognized as a
member of the PTP protein cluster. We reasoned that StAR
expression could be induced by substrate availability and
decreased by substrate shortage, in similarity with other proteins
involved in handling intracellular cholesterol such as ACAT (acyl-
coenzyme A:cholesterol acyltransferase) [19] and the cholesterol
transporter ABCA1 [20]. We used squalestatin to inhibit
endogenous cholesterol biosynthesis and we analysed StAR
expression by western blotting. As shown in figure 4A the analysis
of mitochondrial StAR revealed a decrease of about 50% after a
treatment with squalestatin for 48 and 72 hours, whereas
treatment with vit. D did not affect StAR expression. We then
carried out the quantification of VDR expression in presence of
squalestatin in a time course experiment as shown in figure 4B and
we found that mitochondrial VDR decreased only after 72 hours
of incubation with the drug. In the same conditions VDR
expression analysed in total extracts was never affected, leading to
the conclusion that the decrease of StAR had no direct effect on
VDR expression, but instead it hampered VDR mitochondrial
import by PTP. Finally we checked whether in the last 24 hours of
squalestatin treatment the presence of vit. D could make a
difference in receptor import, but it did not, since mitochondrial
VDR decreased by squalestatin did not change if vit. D was added,
as demonstrated by graph in figure 4C. Representative images of
blots are displayed in figure S2.
Dexamethasone Elicits a Decrease of Mitochondrial StAR
and VDR
We realized that an alternative treatment able to decrease
mitochondrial StAR expression was the incubation with dexa-
methasone (dex), as previously published [21]. We therefore used
dex to confirm the decreased mitochondrial import of VDR seen
in presence of squalestatin. Given the stability of mitochondrial
VDR, an incubation of 72 hour with dex was carried out and the
experiment led to a decrease of mitochondrial StAR along with
mitochondrial VDR, whereas total VDR expression was not
affected, as shown in figure 5. We concluded that dexamethasone
brought about a StAR-dependent reduced mitochondrial import
of VDR.
Genetic Silencing of StAR Reduces VDR Mitochondrial
Import
In order to confirm the physiological relevance of StAR as
mediator of VDR mitochondrial import and to reinforce the data
obtained by pharmacological treatments, we used the lentiviral
delivery system carrying the StAR-specific shRNA to silence the
endogenous expression of StAR in HaCaT cells. We found that
consistently with the results displayed in figures 4–5 silencing of
endogenous StAR impaired the expression of mitochondrial VDR.
As shown in figure 6, five days after infection StAR expression was
abated. Its depletion had severe repercussions on mitochondrial
localization of VDR, whereas it did not interfere with total VDR
protein expression.
Discussion
Few previous reports suggested the extra-nuclear intracellular
distribution of VDR [9–11]. Among them our work on platelets
and megakaryocytes presented the evidences of a mitochondrial
VDR [8]. In this paper we now demonstrate the mitochondrial
localization of VDR also in a human proliferating cell line.
Human keratinocytes are not only able to synthesize vit. D but also
they depend on vit.D/VDR for proliferation and differentiation
[22,23]. We therefore chose to study VDR in the human
keratinocytes HaCaT cell line and besides the classical nuclear
localization we found an abundant mitochondrial expression of the
receptor as well as RXRa its binding partner. VDR distribution
was further demonstrated by silencing experiments and was not
ligand-dependent: the amount of receptor found in mitochondria
was high and not modified by vitamin D. We could define
mitochondrial VDR as a resident protein, in contrast with nuclear
VDR which is described as a ligand-dependent imported
transcription factor. Our work was then focused on identifying
the mechanism of VDR mitochondrial import. Since by the most
used protein subcellular localization prediction methods we could
not find any obvious import sequence at the N-terminal of the
receptor, we considered improbable the import through TOM/
TIM translocase and we investigated another still underestimated
access route to mitochondria: the permeability transition pore
(PTP). This channel is formed by a large and dynamic complex of
proteins (reviewed in [24]), its opening is voltage-dependent and it
is more known for being involved in release of mitochondrial
proteins such as cytochrome C during apoptosis, in translocation
of nucleotides through the complex member adenine nucleotide
translocator ANT and in the transport of cholesterol via another
complex member, StAR. However very few reports have shown
the interaction of mitochondrial proteins with the components of
the channel, suggesting the possibility of the import of proteins
larger than 1.5 kDa via the PTP. For example the tumor necrosis
factor receptor p75NTR was found in mitochondria where
interacts with ANT [25]. Interestingly, there are reports of a link
between PTP opening and mitochondrial localization of proteins.
For example mitochondrial localization of p-glycoprotein (pgp) is
sensitive to selective opener (Atractyloside glycoside, ATR) and
inhibitor (Cyclosporin A, CsA) of mitochondrial permeability
transition pore [26]. Moreover it has been shown that mitochon-
drial permeability transition is required for p53 mitochondrial
translocation [27].
In order to verify whether PTP could have a role in VDR
import, we first demonstrated by immunoprecipitation studies that
VDR and RXRa interacted with PTP by association with VDAC
and StAR. Then we searched the proofs that such a multimer was
functional. We demonstrated that VDR crossed mitochondrial
membranes via PTP by three different sets of experiments: a
pharmacological inhibition of PTP opening with CsA, a down-
regulation of StAR triggered by squalestatin and a decreased
expression of StAR upon treatment with dexamethasone. Every
time we reduced the PTP function mitochondrial levels of VDR
were abated. As for the mitochondrial import of RXRa, the
immunoprecipitation studies suggested its association with PTP,
however the experiments with CsA indicated that the entry via
PTP is a somehow minor event and the main mechanism of
import is different, because it is CHX sensitive and only slightly
modified by CsA. This is in agreement with previous reports
[28,29]. In our experiments mitochondrial p53 was not curtailed
by CsA, but on the contrary closing the PTP had an enhancing
effect on its mitochondrial localization. These results differ from
observations of Liu and coll. [27] because they evaluated p53
import triggered by TPA and after short treatments with CsA. In
our hands PTP closure for 42 hours stabilized mitochondrial p53.
Taken together the results from CHX-CsA experiments were able
to discriminate between proteins crossing mitochondrial mem-
branes via PTP or other mechanisms, and they gave the first
indication on how VDR enters mitochondria. Moreover the same
experiments were important to demonstrate that mitochondrial
VDR Mitochondrial Translocation
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VDR is a rather stable receptor, showing a half-time of about
48 hours.
VDR entry via PTP was confirmed by the subsequent
experiments that decreased the amount of one member of PTP:
StAR. In fact both the treatment with squalestatin and with
dexamethasone reduced mitochondrial VDR, reinforcing thus the
idea that a well functioning PTP was necessary for mitochondrial
compartmentalization of VDR. Since the receptor was abundant
and stable, a decline in its mitochondrial presence was visible only
after a prolonged inhibition of PTP function (48 hours of closure
Figure 4. Effect of squalestatin treatment on StAR and VDR expression. HaCaT cells were treated with squalestatin (SQ) and 100 nM 1,25D3
(D) or left untreated (control, C), harvested and 50 mg of total lysates (tot) or 30 mg of mitochondrial proteins (mitoc) were analysed by western
blotting for StAR and VDR expression. Bands were quantified, normalized for loading as a ratio to actin expression (tot) or VDAC expression (mitoc)
and data plotted on graph as percentage of control. Data represent the mean 6 S.D of three independent experiments. (A) Analysis of StAR
expression in mitochondrial fractions after 48 or 72 hours of treatment with SQ, 24 hours with vit. D or cotreatment in which vit. D was added in the
last 24 hours (SQ+D). (B) VDR expression after squalestatin treatment in a time course experiment. (C) VDR expression after 72 hours of the same
treatments as in (A). 1p,0.01 and **p,0.001 compared to control.
doi:10.1371/journal.pone.0054716.g004
VDR Mitochondrial Translocation
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or 72 hours of lower expression). A confirmation of the data
obtained by pharmacological down-regulation of StAR came from
silencing experiments. StAR knockdown by lentiviral delivery of
shRNA decreased mitochondrial VDR, supporting the role of
StAR in the mechanism of VDR mitochondrial import.
The presence of nuclear receptors in mitochondria was already
described in literature (reviewed in [6]) and this localization is
important for their role in mitochondrial metabolism. Several
papers have described the mitochondrial import and function of
other steroid receptors, such as RXRa, estrogen receptor a and b,
triiodothyronine (T3) receptor, glucocorticoid receptor [30,31].
For some of them a mitochondrial import signal has been
indicated, suggesting a translocase-mediated transport [5] some-
times preceded by partial proteolysis [28,32]. However in many
cases the import mechanism is still obscure. The presented novel
mechanism of entry for VDR could apply to some of them.
In conclusion this paper gives for the first time the evidences of
VDR mitochondrial localization in human proliferating cells and
shows that mitochondrial targeting is mediated by PTP. These
findings open interesting future investigations on PTP function as
transporter and on VDR role in mitochondria.
Supporting Information
Figure S1 Analysis of mitochondrial translocation of
VDR in presence of cyclosporin A. HaCaT cells were treated
with cyclosporin A (CsA), cycloheximide (CHX) or 100 nM
1,25D3 (Vit.D) as indicated and 30 mg of mitochondrial proteins
were analysed by western blotting for VDR, RXRa and p53
expression. VDAC was used as internal control for protein
loading. A representative blot is shown.
(TIF)
Figure S2 Effect of squalestatin treatment on StAR and
VDR expression. HaCaT cells were treated with squalestatin
(SQ) and 100 nM 1,25D3 (D) or left untreated (control, C),
harvested and 50 mg of total lysates (tot) or 30 mg of mitochondrial
proteins (mit) were analysed by western blotting for StAR and
VDR expression. VDAC or actin expression were evaluated as
loading control. A set of representative blots is shown. (A) Analysis
of StAR expression in mitochondrial fractions. (B) VDR
expression after squalestatin treatment in a time course experi-
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